Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

Lignende værker

• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  af: Raschi, Emanuel, et al.
  Udgivet: (2021)
• Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
  af: Raschi, Emanuel, et al.
  Udgivet: (2020)
• Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
  af: Raschi, Emanuel, et al.
  Udgivet: (2020)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  af: Raschi, Emanuel, et al.
  Udgivet: (2019)
• Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
  af: Gatti, Milo, et al.
  Udgivet: (2021)